HYDRATE IT
with Juvéderm® VOLITE™[1]

When you want to
enhance skin quality[1–3*†‡]

Model treated with JUVÉDERM® (including Juvéderm® VOLITE™). Results may vary.

* Juvéderm® VOLITE™ contains lidocaine.[1] The addition of lidocaine does not alter the product's physical properties.[4]

† Study conducted using Juvéderm® VOLITE™ B (without lidocaine).[5]

‡ Skin quality is defined as smoothness (absence of fine lines), hydration and elasticity.[2] Investigator-assessed cheek skin texture (primary endpoint) as a measure of skin smoothness improved in patients at Month 1 (96.2%), Month 4 (76.3%), Month 6 (34.9%) and Month 9 (15.8%).[2]

CA-JUV-2050090
FA-JUV-VOLITEHCPBROCHURE-001-E
Date of preparation: August 2020

Juvéderm® VOLITE™

Allergan Aesthetics
an AbbVie company

Juvéderm®

SKIN IS A FOUNDATION OF BEAUTY[6]

Did you know that **52%* of people feel they have facial skin issues**, such as texture or uneven skin tone?[7*]

What's more, 74%* of people want to improve the look of their facial skin.[7] Your patients may see you with this goal in mind, or they may want different kinds of aesthetic treatments. As part of their aesthetic goal, **you have the opportunity to HYDRATE IT[1] and enhance their skin quality**.[2†‡]

JUVÉDERM® VOLITE™ CAN HYDRATE FROM WITHIN[2‡]

Hyaluronic acid (HA) is said to be an **'ultimate solution' for hydrating the skin**.[8]

To boost hydration[2‡§] and skin quality,[2†§] we have Juvéderm® VOLITE™. It can be injected **under the skin**[1] and deliver **deep hydration**.[2‡§]

Indication[1] visuals are for illustrative purposes only.

* Based on a 2018 Allergan market research study of 14,584 aesthetically aware male and female respondents aged 21–75 (21–65 in the US) in 18 countries.[7]

† Skin quality is defined as smoothness (absence of fine lines), hydration and elasticity.[2] Investigator-assessed cheek skin texture (primary endpoint) as a measure of skin smoothness improved in patients at Month 1 (96.2%), Month 4 (76.3%), Month 6 (34.9%) and Month 9 (15.8%).[2]

‡ Study conducted using Juvéderm® VOLITE™ B (without lidocaine).[5]

§ Based on a study of 131 adult patients who received multiple microdepot injections of Juvéderm® VOLITE™ in the intradermal layer. Cheek skin hydration was measured at a depth of 0.5 mm and 1.5 mm by the MoistureMeterD® instrument at Months 1, 4, 6 and 9.[2]

Allergan Aesthetics
an AbbVie company

SKIN QUALITY
UP CLOSE

See the results of Juvéderm® VOLITE™ treatment in fine detail.



Models only treated with Juvéderm® VOLITE™ for the purpose of these materials. Individual treatment results may vary. After treatment photographs taken 3 weeks after treatment. Patients received 2 mL of Juvéderm® VOLITE™ in the face.

DERMAL HYDRATION* IN 1–3–9[2†‡§]

1 treatment,[†] using **3 mL of Juvéderm® VOLITE™** for the face,[2‡] can result in **dermal hydration for up to 9 months.**[2*§]

Skin is hydrated,[2*] and showed **improved skin texture and less visible fine lines for up to 4 months**.[2§]

WHAT'S MORE, PATIENTS WERE SATISFIED WITH THEIR SKIN FOR UP TO 9 MONTHS.[2¶]

* Based on a study of 131 adult patients who received multiple microdepot injections of Juvéderm® VOLITE™ in the intradermal layer. Cheek skin hydration was measured at a depth of 0.5 mm and 1.5 mm by the MoistureMeterD® instrument at Months 1, 4, 6 and 9.[2]

† After a single treatment, which included initial (n=131) and top-up administered at Day 30 (n=31).[2]

‡ Median volume injected at initial dose was 2.8 mL for the face (1.3 mL per cheek + 0.2 mL forehead), which has been rounded to 3 mL.[2]

§ Study conducted using Juvéderm® VOLITE™ B (without lidocaine).[5]

¶ Based on FACE-Q satisfaction with Skin score of 76.4% of patients (N=127) at Month 9. FACE-Q Satisfaction with Skin score was calculated by summing the responses to the 12 items and converting to a scale score (range: 0–100). For subjects missing <50% of items, missing items were imputed as the mean of non-missing items.[2]

*DERMAL HYDRATION**
THAT CAN LAST UP TO 9 MONTHS[2§‡]

Cheek skin hydration, measured by MoistureMeterD®[2§] was significantly improved from baseline at all time points[2]



Injection site reactions were as expected for dermal filler treatment and were typically mild or moderate.[2] The 3 most reported reactions were:[2]

- **Redness**
- **Swelling**
- **Tenderness**

Adapted from Niforos F *et al.* 2017.[2] N = total sample number.

* Based on a study of 131 adult patients who received multiple microdepot injections of Juvéderm® VOLITE™ in the intradermal layer. Cheek skin hydration was measured at a depth of 0.5 mm and 1.5 mm by the MoistureMeterD® instrument at Months 1, 4, 6 and 9.[2]

† In a prospective, single-centre, single arm study evaluating the safety and effectiveness of Juvéderm® VOLITE™ for treatment of facial fine lines, as measured by changes in skin texture and skin quality. Treatment group (N=131) received initial treatment on Day 0, touch-up treatment at ≈Day 30 if needed for asymmetry correction and optional repeat treatment at Month 9. Primary endpoint: proportion of cheeks with ≥1-point improvement from baseline (responder) in investigator-rated validated Allergan Skin Roughness Scale score at Month 1 after last injection.[2]

§ Paired t-test was used to test for mean changes from baseline.[2]

‡ Study conducted using Juvéderm® VOLITE™ B (without lidocaine).[5]

Juvéderm®

SAFETY INFORMATION

Indications

The JUVÉDERM® family of products are injectable implants, most of which contain Lidocaine intended to reduce the patient's pain during treatment.

Juvéderm® VOLITE™ is used for the treatment of face (cheek and forehead) and neck, by filling of superficial cutaneous depressions such as fine lines and for additional improvement of hydration.

Contraindications

- Eyelid injections
- Injection into blood vessels
- Overcorrection (for all JUVÉDERM® products)
  - Patients with a tendency to develop hypertrophic scarring
  - Patients with known hypersensitivity to hyaluronic acid
  - Women who are pregnant or breastfeeding
  - Children under 18 years of age
- In addition, for JUVÉDERM® products containing Lidocaine:
  - Porphyria or untreated epilepsy
  - Known hypersensitivity to lidocaine or amide-type local anesthetics
- Injection into areas with cutaneous inflammation or infection (e.g. acne, herpes, reaction to surface peels, etc.)
- Simultaneous use with laser treatment, deep chemical peels or dermabrasion

Other relevant warnings and precautions

- No clinical data available on safety or efficacy in patients with:
  - History of autoimmune disease, severe multiple allergies, anaphylactic shock
  - History of streptococcal disease (dual test recommended)
  - Cardiac conduction disorders or acute rheumatic fever with cardiac complications
  - Susceptibility to keloid formation or pigmentation disorders
- No clinical data available on safety or efficacy for:
  - Use in an area previously treated with another filler product or permanent implant
- JUVÉDERM® products containing Lidocaine are not recommended in combination with drugs that reduce or inhibit hepatic metabolism (e.g. cimetidine, beta-blockers, etc.)

- Warn patients on anti-coagulants, acetylsalicylic acid, and nonsteroidal anti-inflammatory drugs of the increased potential risk of hematomas and bleeding
- Do not allow JUVÉDERM® products to come in contact with quaternary ammonium salts such as benzalkonium chloride

Advice to patients

- Avoid taking aspirin or high doses of vitamin C the week before injection
- Do not wear makeup for 12 hours after the injection
- Avoid prolonged exposure to sunlight, UV light, freezing temperatures or using saunas, hammam baths or steam rooms during the two weeks after injection
- Seek medical attention as soon as possible if inflammatory reactions persist for more than one week or other side effects develop

Undesirable effects

- Potential side effects may occur immediately or be delayed
  - Inflammatory reactions including erythema, edema, itching, pain lasting up to one week
  - Injection into mucous membranes of the lips may cause more edema and bruising due to the specific physiology of these tissues. Consider use of preventive anti-inflammatory treatment
  - Hematomas, induration, nodules, staining or discolouration in the injection area
  - Poor or weak restoration effect
  - Necrosis in the glabellar region, abscesses, granuloma and immediate or delayed hypersensitivity have been reported

For more information: Refer to the Directions for Use (DFUs) for the specific JUVÉDERM® products for important information relating to contraindications, precautions, undesirable effects and method of use which have not been discussed in this piece.

The DFUs for each JUVÉDERM® product are also available by calling Allergan Inc. at 1-800-668-6424.

IT'S TIME TO HYDRATE IT[1]

Part of the VYCROSS® collection, from **the world's number one brand of hyaluronic acid facial fillers.**[9]*

1 treatment[2†] session with **3 mL**[2‡] in the face can result in dermal hydration for up to **9 months**.[2§¶]

Can be a treatment for skin conscious patients, or used with other VYCROSS® HA facial fillers.[11–13]

* Based on healthcare professional (HCP) tracking market research, from over 1000 HCPs in the largest 13 aesthetic markets worldwide.[9]
† After a single treatment, which included initial (n=131) and top-up administered at Day 30 (n=31).[2]
‡ Median volume injected at initial dose was 2.8 mL for the face (1.3 mL per cheek + 0.2 mL forehead), which has been rounded to 3 mL.[2]
§ Based on a study of 131 adult patients who received multiple microdepot injections of Juvéderm® VOLITE™ in the intradermal layer. Cheek skin hydration was measured at a depth of 0.5 mm and 1.5 mm by the MoistureMeterD® instrument at Months 1, 4, 6 and 9.[2]
¶ Study conducted using Juvéderm® VOLITE™ B (without lidocaine).[5]

1. Juvéderm® VOLITE™ DFU. 73402ZQ10. Revision 2018-01-19.
2. Niforos F *et al.* Poster Presentation at Beauty Through Science (BTS) Congress, Stockholm, Sweden; 2017.
3. Allergan. Unpublished Data. INT/0078/2017(1). Juvéderm® VOLITE™ treatment area. Mar 2019.
4. Raspaldo H *et al. J Cosmet Dermatol.* 2010;9:11–15.
5. Allergan. Data on File. INT/0773/2016(1). Juvéderm® VOLITE™ B without lidocaine. Sep 2018.
6. Swift A and Remington K. *Clin Plast Surg.* 2011;38:347–77.
7. Allergan. Unpublished Data. Allergan 360 Report lower face data. INT-NON-1950020. May 2019.
8. Jegasothy SM *et al. J Clin Aesthet Dermatol.* 2014;7(3):27–9.
9. Allergan. Unpublished Data. INT/0771/2016(2). JUVÉDERM®, the world's leading brand of hyaluronic acid facial fillers. Feb 2019.
10. Juvéderm® VOLBELLA® with lidocaine DFU. 72525ZQ13. Revision 2018-06-12.
11. Juvéderm® VOLIFT® with lidocaine DFU. 72521ZQ13, Revision 2019-06-28.
12. Juvéderm® VOLUMA® with lidocaine DFU. 72459ZQ13. Revision 2018-06-12.
13. Juvéderm® VOLUX® DFU. 73534ZQ10. Revision 2019-02-12.